Lixte terminates City of Hope trial agreement for LB-100 Phase 1b; seeks new sites

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Terminated Clinical Research Support Agreement with City of Hope effective July 8, 2024.
Agreement covered Phase 1b trial of LB-100 combined with Carboplatin/Etoposide/Atezolizumab for extensive-stage small cell lung cancer.
Company plans to explore alternative clinical trial sites to continue the study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.